Zentraxa

About:

Zentraxa has specialise in the design, production and testing of complex novel peptides.

Top Investors: Future Planet Capital, Parkwalk Advisors, Newable Private Investing, Bristol Private Equity Club, Empirical Ventures

Description:

Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.

Total Funding Amount:

500000 GBP

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Bristol, Bristol, City of, United Kingdom

Founded Date:

2017-01-01

Founders:

Martin Challand, Paul Race, Steven Burston

Number of Employees:

11-50

Last Funding Date:

2023-05-27

IPO Status:

Private

Industries: